Re-circulation of lymphocytes mediated by sphingosine-1-phosphate receptor-1 contributes to resistance against experimental infection with the protozoan parasite Trypanosoma cruzi

Vaccine

Volumn 30, Issue 18, 2012, Pages 2882-2891

  Dominguez, Mariana R ^a   Ersching, Jonatan ^a   Lemos, Ramon ^a   Machado, Alexandre V ^b   Bruna Romero, Oscar ^c   Rodrigues, Mauricio M ^a   de Vasconcelos, José Ronnie C ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

CD8; FTY720; Gene based vaccines; Protozoan

Indexed keywords

EPITOPE; FINGOLIMOD; GLYCOPROTEIN P 15095; PARASITE ANTIGEN; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHAGAS DISEASE; CONTROLLED STUDY; FEMALE; INFECTION SENSITIVITY; LYMPH NODE; LYMPHOCYTE RECIRCULATION; MOUSE; NONHUMAN; PARASITEMIA; PRIORITY JOURNAL; SPLEEN; T LYMPHOCYTE ACTIVATION; TRYPANOSOMA CRUZI; UPREGULATION;

ANIMALS; ANTIGENS, CD11C; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; LYMPH NODES; MICE; MICE, INBRED C57BL; RECEPTORS, LYSOSPHINGOLIPID; SPLEEN; TRYPANOSOMA CRUZI;

EID: 84859004243     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.02.037     Document Type: Article

References (52)

1. Tarleton R.L. Immune system recognition of Trypanosoma cruzi. Curr Opin Immunol 2007, 9:430-434.
2. + T cell immunity - an infection model for developing T cell vaccine. Parasitol Int 2008, 57:38-48.
3. Padilla A.M., Bustamante J.M. Tarleton RL CD8+ T cells in Trypanosoma cruzi infection. Curr Opin Immunol 2009, 21:385-390.
4. Junqueira C., Caetano B., Bartholomeu D.C., et al. The endless race between Trypanosoma cruzi and host immunity: lessons for and beyond Chagas disease. Expert Rev Mol Med 2010, 12:e29.
5. Arnholdt A.C., Piuvezam M.R., Russo D.M., Lima A.P., Pedrosa R.C., Reed S.G., et al. Analysis and partial epitope mapping of human T cell responses to Trypanosoma cruzi cysteinyl proteinase. J Immunol 1993, 151:3171-3179.
6. Michailowsky V., Luhrs K., Rocha M.O., Fouts D., Gazzinelli R.T., Manning J.E. Humoral and cellular immune responses to Trypanosoma cruzi-derived paraflagellar rod proteins in patients with Chagas' disease. Infect Immun 2003, 71:3165-3171.
7. Millar A.E., Wleklinski-Lee M., Kahn S.J. The surface protein superfamily of Trypanosoma cruzi stimulates a polarized Th1 response that becomes anergic. J Immunol 1999, 162:6092-6099.
8. Ribeirão M., Pereira-Chioccola V.L., Rénia L., Schenkman S., Rodrigues M.M. Chagasic patients develop type i immune response to Trypanosoma Cruzi trans-sialidase. Parasite Immunol 2000, 22:49-53.
9. Cuellar A., Rojas F., Bolaños N., et al. Natural CD4(+) T-cell responses against Trypanosoma cruzi KMP-11 protein in chronic chagasic patients. Immunol Cell Biol 2009, 87:149-153.
10. + cytotoxic T cells after infection with Trypanosoma cruzi in naive or vaccinated mice. Infect Immun 2006, 74:2477-2481.
11. Martin D.L., Weatherly D.B., Laucella S.A., Cabinian M.A., Crim M.T., et al. CD8+ T-Cell responses to Trypanosoma cruzi are highly focused on strain-variant trans-sialidase epitopes. PLoS Pathog 2006, 2(8):e77.
12. Tzelepis F., Persechini P.M., Rodrigues MM Modulation of CD4(+) T cell-dependent specific cytotoxic CD8(+) T cells differentiation and proliferation by the timing of increase in the pathogen load. PLoS One 2007, 2(4):e393.
13. Tzelepis F., de Alencar B.C., Penido M.L., et al. Infection with Trypanosoma cruzi restricts the repertoire of parasite-specific CD8+ T cells leading to immunodominance. J Immunol 2008, 180:1737-1748.
14. Bixby L.M., Tarleton R.L. Stable CD8+ T cell memory during persistent Trypanosoma cruzi infection. J Immunol 2008, 181:2644-2650.
15. Rosenberg C.S., Martin D.L., Tarleton R.L. CD8+ T cells specific for immunodominant trans-sialidase epitopes contribute to control of Trypanosoma cruzi infection but are not required for resistance. J Immunol 2010, 185:560-568.
16. Freire-de-Lima L., Alisson-Silva F., Carvalho S.T., et al. Trypanosoma cruzi subverts host cell sialylation and may compromise antigen-specific CD8+ T cell responses. J Biol Chem 2010, 285:13388-13396.
17. Oliveira A.C., de Alencar B.C., Tzelepis F., et al. Impaired innate immunity in Tlr4(-/-) mice but preserved CD8+ T cell responses against Trypanosoma cruzi in Tlr4-, Tlr2-,Tlr9- or Myd88-deficient mice. PLoS Pathog 2010, 6(4):e1000870.
18. Rodrigues M.M., de Alencar B.C., Claser C., Tzelepis F. Immunodominance: a new hypothesis to explain parasite escape and host/parasite equilibrium leading to the chronic phase of Chagas' disease. Braz J Med Biol Res 2009, 42:220-223.
19. Vasconcelos J.R., Hiyane M.I., Marinho C.R., et al. Protective immunity against Trypanosoma cruzi infection in a highly susceptible mouse strain after vaccination with genes encoding the amastigote surface protein-2 and trans-sialidase. Hum Gene Ther 2004, 15:878-886.
20. Miyahira Y., Takashima Y., Kobayashi S., et al. Immune responses against a single CD8+-T-cell epitope induced by virus vector vaccination can successfully control Trypanosoma cruzi infection. Infect Immun 2005, 73:7356-7365.
21. Hoft D.F., Eickhoff C.S., Giddings O.K., Vasconcelos J.R., Rodrigues M.M. Trans-sialidase recombinant protein mixed with CpG motif-containing oligodeoxynucleotide induces protective mucosal and systemic Trypanosoma cruzi immunity involving CD8+ CTL and B cell-mediated cross-priming. J Immunol 2007, 179:6889-6900.
22. Machado A.V., Cardoso J.E., Claser C., et al. Long-term protective immunity induced against Trypanosoma cruzi infection after vaccination with recombinant adenoviruses encoding amastigote surface protein-2 and trans-sialidase. Hum Gene Ther 2006, 17:898-908.
23. Araújo A.F., de Alencar B.C., Vasconcelos J.R., et al. CD8+-T-cell-dependent control of Trypanosoma cruzi infection in a highly susceptible mouse strain after immunization with recombinant proteins based on amastigote surface protein 2. Infect Immun 2005, 73:6017-6025.
24. Cazorla S.I., Frank F.M., Becker P.D., et al. Redirection of the immune response to the functional catalytic domain of the cystein proteinase cruzipain improves protective immunity against Trypanosoma cruzi infection. J Infect Dis 2010, 202:136-144.
25. de Alencar B.C., Persechini P.M., Haolla F.A., et al. Perforin and gamma interferon expression are required for CD4+ and CD8+ T-cell-dependent protective immunity against a human parasite, Trypanosoma cruzi, elicited by heterologous plasmid DNA prime-recombinant adenovirus 5 boost vaccination. Infect Immun 2009, 77:4383-4395.
26. Takagi H., Fukaya T., Eizumi K., et al. Plasmacytoid dendritic cells are crucial for the initiation of inflammation and T cell immunity in vivo. Immunity 2011, 35(6):958-971.
27. Rosen H., Sanna G., Alfonso C. Egress: a receptor-regulated step in lymphocyte trafficking. Immunol Rev 2003, 195:160-177.
28. Cyster J.G. Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu Rev Immunol 2005, 23:127-159.
29. Brinkmann V., Cyster J.G., Hla T. FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant 2004, 4:1019-1025.
30. Jung S., Unutmaz D., Wong P., et al. In vivo depletion of CD11c(+) dendritic cells abrogates priming of CD8(+) T cells by exogenous cell-associated antigens. Immunity 2002, 17:211-220.
31. Dominguez M.R., Silveira E.L., de Vasconcelos J.R., de Alencar B.C., Machado A.V., Bruna-Romero O., Gazzinelli R.T., Rodrigues M.M. Subdominant/cryptic CD8T cell epitopes contribute to resistance against experimental infection with a human protozoan parasite. PLoS One 2011, 6:e22011.
32. + T cell responses in Trypanosoma cruzi infection. J Immunol 2009, 183:1245-1252.
33. Chakravarty S., Cockburn I.A., Kuk S., Overstreet M.G., Sacci J.B. Zavala F CD8+ T lymphocytes protective against malaria liver stages are primed in skin-draining LN. Nat Med 2007, 13:1035-1041.
34. Pinschewer D.D., Ochsenbein A.F., Odermatt B., Brinkmann V., Hengartner H., et al. FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J Immunol 2000, 164:5761-5770.
35. Kursar M., Jnner N., Pfeffer K., Brinkmann V., Kaufmann S.H., et al. Requirement of secondary lymphoid tissues for the induction of primary and secondary T cell responses against Listeria monocytogenes. Eur J Immunol 2008, 38:127-138.
36. Lopes C.T., de Paula D.M.B., Cury P.M., Valero-Lapchik V.B. Bueno V Leishmania (Leishmania) amazonensis infection in mice treated with FTY720. Transplant Proc 2010, 42:578-581.
37. Rigato P.O., de Alencar B.C., de Vasconcelos J.R., et al. Heterologous plasmid DNA prime-recombinant human adenovirus 5 boost vaccination generates a stable pool of protective long-lived CD8(+) T effector memory cells specific for a human parasite, Trypanosoma cruzi. Infect Immun 2011, 79:2120-2130.
38. + T lymphocytes in vaccinated, simian human immunodeficiency virus-infected rhesus monkeys. J Immunol 2006, 176:5338-5345.
39. Casimiro D.R., Chen L., Fu T.M., et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 2003, 77:6305-6313.
40. Casimiro D.R., Wang F., Schleif W.A., et al. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag. J Virol 2005, 79:15547-15555.
41. Geisbert T.W., Bailey M., Geisbert J.B., et al. Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates. J Virol 2010, 84:10386-10394.
42. Gilbert S.C., Schneider J., Hannan C.M., et al. Enhanced CD8T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunization regimes. Vaccine 2002, 20:1039-1045.
43. Hensley L.E., Mulangu S., Asiedu C., et al. Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species. PLoS Pathog 2010, 6:e1000904.
44. + central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 2006, 312:1530-1533.
45. Wilson N.A., Reed J., Napoe G.S., et al. Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J Virol 2006, 80:5875-5885.
46. Freel S.A., Lamoreaux L., Chattopadhyay P.K., et al. Phenotypic and functional profile of HIV-inhibitory CD8T cells elicited by natural infection and heterologous prime/boost vaccination. J Virol 2010, 84:4998-5006.
47. Jaoko W., Karita E., Kayitenkore K., et al. Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. PLoS One 2010, 5:e12873.
48. Koup R.A., Roederer M., Lamoreaux L., Fischer J., Novik L., et al. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS One 2010, 5(2):e9015.
49. Schooley R.T., Spritzler J., Wang H., et al. AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein. J Infect Dis 2010, 202:705-716.
50. Wolf A.M., Eller K., Zeiser R., Dürr C., Gerlach U.V., Sixt M., et al. The sphingosine 1-phosphate receptor agonist FTY720 potently inhibits regulatory T cell proliferation in vitro and in vivo. J Immunol 2009, 183:3751-3760.
51. Sehrawat S., Rouse B.T. Anti-inflammatory effects of FTY720 against viral-induced immunopathology: role of drug-induced conversion of T cells to become Foxp3+ regulators. J Immunol 2008, 180:7636-7647.
52. Choi J.W., Gardell S.E., Herr D.R., Rivera R., Lee C.W., Noguchi K., et al. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci U S A 2011, 108:751-756.